InMed Pharmaceuticals Inc. (INM) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
INM Revenue Growth
INM Revenue Analysis (2014–2025)
As of May 7, 2026, InMed Pharmaceuticals Inc. (INM) generated trailing twelve-month (TTM) revenue of $4.2 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q2 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, INM's historical revenue data shows a 3-year CAGR of +65.5%. The company achieved its highest annual revenue of $4.9 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including YCBD (+26075.4% YoY), ATAI (+811.8% YoY), and SNDL (+1.1% YoY), INM has underperformed the peer group in terms of revenue growth. Compare INM vs YCBD →
INM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| INMCurrent | $4M | -100.0% | - | -160.2% | |
 YCBD | $19M | +26075.4% | -14.5% | -11.3% | |
 ATAI | $308,000 | +811.8% | - | -33341.2% | |
 SNDL | $946M | +1.1% | +73.1% | -0.5% |
INM Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.9M | +7.5% | $1.7M | 34.5% | $-7,917,995 | -160.2% |
| 2024 | $4.6M | +11.2% | $1.1M | 23.9% | $-8,134,430 | -176.9% |
| 2023 | $4.1M | +279.6% | $1.4M | 33.9% | $-8,378,787 | -202.6% |
| 2022 | $1.1M | - | $544K | 49.9% | $-13,791,756 | -1266.0% |
| 2021 | $0 | - | $0 | - | $-12,171,142 | - |
| 2020 | $0 | - | $-183,090 | - | $-9,150,862 | - |
| 2019 | $0 | - | $-93,940 | - | $-10,358,873 | - |
| 2018 | $0 | - | $-92,777 | - | $-6,778,130 | - |
| 2017 | $0 | - | $0 | - | $-3,439,445 | - |
| 2016 | $0 | - | $0 | - | $-1,837,361 | - |
See INM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINM — Frequently Asked Questions
Quick answers to the most common questions about buying INM stock.
Is INM's revenue growth accelerating or slowing?
INM revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $4M. This reverses the prior growth trend.
What is INM's long-term revenue growth rate?
InMed Pharmaceuticals Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is INM's revenue distributed by segment?
INM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.